| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net revenue | 2,916 | - |
| Cost of revenues | 1,045 | - |
| Personnel-related expenses and board fees | 9,493 | - |
| Professional fees, legal, and outside services | 5,448 | - |
| Facilities and insurance | 1,362 | - |
| Laboratory supplies and expenses | 1,956 | - |
| Marketing and advertising | 321 | - |
| Travel and entertainment | 639 | - |
| Other segment items | 148 | - |
| Segment loss from operations | -17,496 | - |
| Depreciation and amortization expenses | 1,634 | - |
| Stock-based compensation | 1,498 | - |
| Change in fair value of contingent consideration | 7,061 | - |
| Impairment loss on held for sale assets | 0 | - |
| Loss from operations | -27,689 | - |
| Interest expense | -83 | - |
| Other income, net | 505 | - |
| Income taxes | 0 | - |
| Net loss | -27,267 | -16,413 |
| Depreciation and amortization expense | 1,627 | 1,043 |
| Amortization of intangible assets | 7 | 7 |
| Stock-based compensation | 1,498 | 977 |
| Equity compensation for bonus awards and consulting services | 126 | 88 |
| Change in fair value of contingent consideration | 7,061 | 3,683 |
| Impairment loss on held for sale assets | 0 | 0 |
| Unrealized currency translation losses | -170 | - |
| Accounts receivable | -1,355 | -1,101 |
| Inventories | 61 | 283 |
| Prepaid expenses and other assets | 124 | 189 |
| Accounts payable and accrued liabilities | -909 | -2,086 |
| Operating lease assets and liabilities | -122 | -65 |
| Net cash used in operating activities | -16,639 | -12,137 |
| Machinery and equipment purchases, and construction in progress | 1,706 | 656 |
| Net cash used in investing activities | -1,706 | -656 |
| Proceeds from sale of common shares | 29,143 | 29,143 |
| Financing costs to issue common shares | 487 | 487 |
| Proceeds from sale of common shares under at-the-market transactions | 0 | - |
| Financing costs for at-the-market sales | 0 | - |
| Redemption of series a redeemable convertible preferred shares | 0 | 0 |
| Repayment of financing lease obligations | 332 | 212 |
| Net provided by financing activities | 28,324 | 28,444 |
| Effect of exchange rate changes on cash and cash equivalents | -105 | - |
| Net change in cash, cash equivalents and restricted cash | 9,874 | 15,651 |
| Cash and cash equivalents at beginning of period | 10,336 | - |
| Cash and cash equivalents at end of period | 20,210 | - |
Insight Molecular Diagnostics Inc. (IMDX)
Insight Molecular Diagnostics Inc. (IMDX)